Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
批准号:
9754043
负责人:
Wei Gu
金额:
$28.46万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2023-07-31
关键词:
AftercareAllelesAreaBioinformaticsBiological MarkersBiometryBiopsyCRISPR/Cas technologyCaliforniaCancer BiologyCancer DetectionCancer DiagnosticsCancer EtiologyCancer PatientCellsClinicalClinical ManagementClinical ResearchCommunitiesComorbidityCopy Number PolymorphismCross-Sectional StudiesDNADNA MarkersData CollectionDetectionDevelopmentDevelopment PlansDiagnosisDiagnosticDoctor of PhilosophyEnvironmentFive-Year PlansFosteringFoundationsGenesGenomicsGoalsHigh-Throughput Nucleotide SequencingHypermethylationIncidental FindingsIndividualK-Series Research Career ProgramsKnowledgeLaboratoriesMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMedicineMentorsMentorshipMetagenomicsMethodsMethylationMolecularNoiseNon-MalignantNucleic AcidsOperative Surgical ProceduresPathologistPathologyPatientsPatternPhysiciansPlasmaPoint MutationPositioning AttributePromoter RegionsProstateProstatectomyPublic HealthPublishingRadical ProstatectomyResearchResearch DesignRiskRisk AssessmentRisk stratificationSamplingSan FranciscoScientistScreening for cancerSiteTechniquesTestingTissuesTrainingTranslatingUniversitiesUrineValidationWorkactive methodbasecancer biomarkerscancer carecareer developmentcell free DNAearly screeningexperiencegenome sequencinggenome-widehigh riskimprovedinnovationmenmethylation biomarkermethylation patternmolecular pathologymortalitymultidisciplinarynew technologynext generation sequencingnoninvasive diagnosisnoveloncologyovertreatmentprenatalpreservationprognosticpromoterprostate cancer progressionprostate cancer riskprostate surgeryside effectskillssuccesstooltumortumor DNAwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Every year, more than 161,000 men in the U.S. are diagnosed with prostate cancer. While prostate
cancer remains a significant cause of cancer related mortality, early screening efforts are hampered by
the fact that the majority of cases are not imminently deadly and active treatments or re-biopsies have
adverse side effects. The goal of this proposal is to pioneer new non-invasive diagnostics to distinguish
between high-risk versus low-risk prostate cancers in order to guide clinical management.
The core hypothesis of this proposal is that copy number variations and methylation markers can be
found non-invasively in circulating nucleic acids as a surrogate for invasive tissue markers, and these
markers can risk stratify localized prostate cancers. The first aim will evaluate two non-invasive
biomarkers for prostate cancer using next-generation sequencing (NGS)-based approaches. Plasma
and urine samples will be tested for copy number variations and methylation markers, and compared
against concurrent prostate cancer tissue taken from prostate surgery. The second aim will evaluate
the non-invasive approaches in the first aim for the ability to risk stratify localized prostate cancer in a
cross-sectional study.
In this K08 Mentored Clinical Scientist Research Career Development Award application, the
applicant, Wei Gu, MD, PhD, is a board certified Clinical Pathologist at UCSF Department of Laboratory
Medicine. This proposal encompasses a five-year plan to enhance his research and professional skills
with the goal of becoming an independent physician-scientist focused on advancing non-invasive
testing using cell-free nucleic acids as cancer biomarkers.
Essential components of the career development plan are: (1) mentorship from a multidisciplinary team
of scientists and physician-scientists with expertise in advanced molecular techniques, bioinformatics,
biostatistics, and clinical study design; (2) formal didactics to expand on knowledge in clinical study
design, cancer biology, bioinformatics, and professional development; (3) laboratory testing and
analysis of cell-free DNA as biomarkers for prostate cancer; (4) professional development in the
transition to independence, and (5) data collection for an R01 application. A mentorship and
multidisciplinary scientific committee has been assembled to facilitate the proposal aims and
progression towards independence. This plan will be implemented at University of California, San
Francisco, which provides an exceptional research environment, state-of-art facilities, and a supportive
scientific community that will be an ideal environment to foster career development and project
success.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
-
批准号:10439098
-
项目类别:
-
资助金额:$46.84万
-
财政年份:2022
-
负责人:Wei Gu
-
依托单位:
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
-
批准号:10588175
-
项目类别:
-
资助金额:$45.9万
-
财政年份:2022
-
负责人:Wei Gu
-
依托单位:
p53-mediated metabolic regulation in tumor suppression
-
批准号:10474447
-
项目类别:
-
资助金额:$95.26万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
p53-mediated metabolic regulation in tumor suppression
-
批准号:10663249
-
项目类别:
-
资助金额:$95.26万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
-
批准号:10093308
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
p53-mediated metabolic regulation in tumor suppression
-
批准号:10296735
-
项目类别:
-
资助金额:$57.08万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
-
批准号:10543758
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
-
批准号:10321531
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:10301134
-
项目类别:
-
资助金额:$27.37万
-
财政年份:2020
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:10217044
-
项目类别:
-
资助金额:$28.37万
-
财政年份:2020
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:10456843
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2020
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:9981707
-
项目类别:
-
资助金额:$1.09万
-
财政年份:2018
-
负责人:Wei Gu
-
依托单位:
p53 acetylation in ferroptosis and tumor suppression
-
批准号:10051413
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Wei Gu
-
依托单位:
Mechanisms of targeting oncoprotein SET in tumor suppression
-
批准号:10117198
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Wei Gu
-
依托单位:
Mechanisms of targeting oncoprotein SET in tumor suppression
-
批准号:9889054
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Wei Gu
-
依托单位:
HAUSP inhibitors in p53-wild type and p53-mutant tumors
-
批准号:8861228
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:Wei Gu
-
依托单位:
HAUSP inhibitors in p53-wild type and p53-mutant tumors
-
批准号:9054821
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:Wei Gu
-
依托单位:
Regulation of SLC7A11 by p53 in cancer metabolism
-
批准号:9184541
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:Wei Gu
-
依托单位:
Regulation of Mdmx stability and subcellular localization by ubiquitination
-
批准号:8271769
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2012
-
负责人:Wei Gu
-
依托单位:
Mechanisms of novel cancer targets in ARF-mediated tumor suppression
-
批准号:8535139
-
项目类别:
-
资助金额:$31.21万
-
财政年份:2012
-
负责人:Wei Gu
-
依托单位:
海外基金